Roche reports continued year-on-year growth in 2017

Roche has announced its financial results for the 2017 business year, during which it generated 12-month group sales to CHF 53.3 billion (GBP 40.3 billion).

This represented a year-on-year increase of five percent, with both its pharmaceuticals and diagnostics divisions experiencing similar growth rates. Sales of drug brands such as Ocrevus, Tecentriq, Perjeta and Alecensa were cited as key drivers.

Highlights of the year include the receipt of key regulatory approvals for new medicines Ocrevus and Hemlibra and line extensions of existing products like Perjeta, while a Tecentriq/Avastin combination has shown promise in the treatment of lung and kidney cancer.

In 2018, Roche expects sales to grow in the stable to low-single-digit range at constant exchange rates, while earnings per share are targeting high single-digit growth.

Severin Schwan, Roche's chief executive officer, said: "In 2017, we made significant progress, with good growth in both divisions driven by newly launched medicines and tests."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.